Novo Nordisk Pharmatech brings advanced insights on recombinant insulin to BPI Europe, Amsterdam
News | Novo Nordisk Pharmatech A/S
APRIL 17, 2018
Bagsvaerd, Denmark: – Novo Nordisk Pharmatech, will exhibit at Aprils’s high prestige BioProcess International summit in Amsterdam to show the power of its recombinant insulin to optimize cell density and viability in serum free growth media.
Insulin Sales Manager Magnus Franzmann and Product Manager Sara Goualdoni will lead the Novo Nordisk Pharmatech team at Booth 108 at Amsterdam’s RAI Center.
They will be showcasing the company’s new recombinant insulin as a key component in innovative biologics and pharmaceutical grade Quaternary ammonium compounds.
CHO cell study
The innovative Danish CMO, which is one of the world’s leading suppliers of recombinant insulin in cell culture media powering biopharma blockbuster drugs worldwide, will also post a study, Increase viable CHO cell density by supplementation with recombinant Insulin Human AF.
The main objective of the study was to investigate the effect of insulin as a supplement to improve cell culture media growth and demonstrated that insulin has a positive effect on the CHO cell lines.
cGMP MAbs and vaccines manufacture
“This event gives us a great opportunity to reach out to biopharmaceutical companies working in cell line development. Our insulin can help them enhance and optimize their cell line media growth,” said Sara Goualdoni.
“Our new recombinant insulin can be used in cGMP manufacture of monoclonal antibodies, virus vaccines, gene therapy products and many other biological drug products approved by regulatory bodies worldwide, including FDA and EMA,” Ms. Goualdoni.
About Novo Nordisk Pharmatech
Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, and now part of the Novo Nordisk pharmaceutical group since its acquisition in 1986. On September1, 2015, the company became Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.
The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.
All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.
For Financial Year 2016, Novo Nordisk Pharmatech reported world sales totaling 669 million Danish kroner (DEK) with more than half of all sales recorded in North America.
About BioProcess International Europe 2018
Now in its 14th year, the BioProcess International European Summit (BPI Europe) will host more than 900 bioprocessing professionals, representing some 275 orgaqnizations from academia and industry.
BPI Europe 2018 is a three-day event opening April 23 at the RAI exhibition center in Amsterdam.
The conference features four major streams on Cell Culture & Upstream Process Development, Downstream Processing, Raw Materials and Cell Line Development & Engineering, along with numerous keynote speeches posterpresentations, and an exhibition: all part of the conference’s mission to connect the biopharmaceutical industry with new ideas and innovations across all phases of bioprocess development.
A sister American summit, BPI West, opens March 19 at the Union Square Hilton, San Francisco,
Informa Knect organizes both events. More information: https://lifesciences.knect365.com/bpieurope/.
Vanessa León, Marketing Manager, Novo Nordisk Pharmatech A/S
Tel:+45 404 262 84
Click on Novo Nordisk Pharmatech brings new recombinant insulin to Biologics World Korea for more information.
Click on Novo Nordisk Pharmatech to contact the company directly.